Loading...

A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial

Studies suggest that patients with relapsing-remitting multiple sclerosis (RRMS) who do not benefit from other disease-modifying treatments (DMTs) may benefit from converting to glatiramer acetate (GA). COPTIMIZE was a 24-month observational study designed to assess the disease course of patients co...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Neurol
Main Authors: Ziemssen, Tjalf, Bajenaru, Ovidiu A., Carrá, Adriana, de Klippel, Nina, de Sá, João C., Edland, Astrid, Frederiksen, Jette L., Heinzlef, Olivier, Karageorgiou, Klimentini E., Lander Delgado, Rafael H., Landtblom, Anne-Marie, Macías Islas, Miguel A., Tubridy, Niall, Gilgun-Sherki, Yossi
Format: Artigo
Sprog:Inglês
Udgivet: Springer Berlin Heidelberg 2014
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4221652/
https://ncbi.nlm.nih.gov/pubmed/25119836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00415-014-7446-0
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!